<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Jacqz-Aigrain, Evelyne</dc:creator>
  <dc:creator>Leroux, Stéphanie</dc:creator>
  <dc:creator>Thomson, Alison H</dc:creator>
  <dc:creator>Allegaert, Karel</dc:creator>
  <dc:creator>Capparelli, Edmund V</dc:creator>
  <dc:creator>Biran, Valérie</dc:creator>
  <dc:creator>Simon, Nicolas</dc:creator>
  <dc:creator>Meibohm, Bernd</dc:creator>
  <dc:creator>Lo, Yoke-Lin</dc:creator>
  <dc:creator>Marques, Remedios</dc:creator>
  <dc:creator>Peris, José-Esteban</dc:creator>
  <dc:creator>Lutsar, Irja</dc:creator>
  <dc:creator>Saito, Jumpei</dc:creator>
  <dc:creator>Nakamura, Hidefumi</dc:creator>
  <dc:creator>van den Anker, Johannes N</dc:creator>
  <dc:creator>Sharland, Mike</dc:creator>
  <dc:creator>Zhao, Wei</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">&lt;jats:title&gt;Abstract&lt;/jats:title&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Objectives&lt;/jats:title&gt;
                  &lt;jats:p&gt;In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Methods&lt;/jats:title&gt;
                  &lt;jats:p&gt;A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Results&lt;/jats:title&gt;
                  &lt;jats:p&gt;A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &amp;lt;35 weeks PMA and 15 mg/kg q8h if ≥35 weeks PMA) achieved the AUC0–24 target earlier than a standard ‘Blue Book’ dosage regimen in &amp;gt;89% of the treated patients.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Conclusions&lt;/jats:title&gt;
                  &lt;jats:p&gt;The results of a population meta-analysis of vancomycin data have been used to develop a new dosing regimen for neonatal use and to assist in the design of the model-based, multinational European trial, NeoVanc.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/232021</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkz158</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0305-7453</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Journal of Antimicrobial Chemotherapy. - Oxford University Press (OUP). - 2019, vol. 74, no. 8, p. 2128-2138</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Pharmacology (medical)</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Pharmacology</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Infectious Diseases</dc:subject>
  <dc:title xmlns:ns4="xml" ns4:lang="en">Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
